Swiss pharmaceutical company Novartis has announced it will take a charge of $590 million (SFr573 million) in the third quarter as it discontinued two drugs.
This content was published on
1 minute
swissinfo.ch and agencies
But it added that the charge would be partially offset by a $390 million gain to be booked in the fourth quarter from its divestment of overactive bladder treatment Enablex to Warner Chilcott.
Novartis said in a statement it was stopping Mycograb, an antifungal agent, resulting in a charge of about $360 million.
The Basel-based firm also said it and Human Genome Sciences had decided to stop development of albinterferon alfa-2b for the treatment of adults with chronic hepatitis C, resulting in a write-down of some $230 million.
The reason cited was feedback from regulators in Europe and the United States, as well as new study data,
Albinterferon alfa-2b is known by its brand name Joulferon in Europe and Zalbin in the US.
Popular Stories
More
Swiss Abroad
How centuries of Swiss emigrants left their mark on the US
Bodycams: essential for good law enforcement, or a privacy risk?
Did you ever come across bodycams in your place of residence and if so, how do you think the use of bodycams alter the relationship between the public and (transport) police?
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis to pay millions for sex discrimination
This content was published on
The damages are to be divided between about 5,600 women employees of the Novartis Pharmaceuticals Corporation, a United States affiliate of the Novartis group, covered by the 2004 class action lawsuit. Another $3.36 million in compensatory damages was awarded to 12 former sales reps who testified on behalf of others in the joint suit. On…
This content was published on
Having trailed behind Roche over the last few years, Novartis appeared to have turned a corner with a record-breaking performance in 2009. Roche is tipped to amply recoup the acquisition costs that dented its 2009 profits. Both Basel-based firms are standing on solid foundations and are poised to reap strong benefits in the next two…
This content was published on
Joe Jimenez, a 50-year-old American two years into his tenure as CEO of the pharmaceuticals division, was handed the job on Tuesday after chief executive Daniel Vasella announced he was stepping down on February 1. Vasella, 56, has held the job for 14 years and will remain chairman. Chief operating officer Jörg Reinhardt, who had…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.